Tendersinfo Gulf

Filter Search

Healthcare and Medical

Location Summary Deadline
Germany Conclusion Of A Non-exclusive Discount Agreement In Accordance With Section 130a Paragraph 8 Sgb V For The Active Ingredient Tildrakizumab, Atc L04ac17 For The Period January 1st, 2026 - December 31st, 2027 2026-05-26
Germany Conclusion Of A Non-exclusive Discount Agreement In Accordance With Section 130a Paragraph 8 Sgb V For The Active Ingredient Buserelin, Atc L02ae01 For The Period January 1st, 2026 - December 31st, 2027 2026-05-26
Germany Conclusion Of A Non-exclusive Discount Agreement In Accordance With Section 130a Paragraph 8 Sgb V For The Active Ingredient Paliperidone (exclusively 3-month Depot), Atc N05ax13 For The Period January 1st, 2026 - December 31st, 2027 2026-05-26
Germany Conclusion Of A Non-exclusive Discount Agreement In Accordance With Section 130a Paragraph 8 Sgb V For The Active Ingredient Dimethyl Fumarate, Atc D05bx02 For The Period January 1st, 2026 - December 31st, 2027 2026-05-26
Germany Conclusion Of Non-exclusive Discount Agreements According To § 130a Para. 8 Sgb V For The Mentioned Active Ingredients With The Possibility Of Conclusion Within The Framework Of The So-called Open House Procedure. 2026-05-26
Spain Dynamic System For The Acquisition Of External Occupational Risk Prevention Services. 2026-05-26
United States Transitional Assistance 2025 2026-05-26
Germany Conclusion Of A Non-exclusive Discount Agreement According To § 130a Para. 8 Sgb V For Pharmaceuticals With The Active Ingredient Ranibizumab (atc Code 2026-05-26
Germany Conclusion Of A Non-exclusive Discount Agreement In Accordance With Section 130a Paragraph 8 Sgb V For The Active Ingredient Lebrikizumab, Atc D11ah10 For The Period January 1st, 2026 - December 31st, 2027 2026-05-27
Germany Open House Drug Discount Agreements For The Active Ingredient Aflibercept, With A Potency Of 40 Mg/ml, Atc S01la05 2026-05-27
Whats app